Opendata, web and dolomites

MP-101

a novel drug for prevention and treatment peripheral neuropathy symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MP-101 project word cloud

Explore the words cloud of the MP-101 project. It provides you a very rough idea of what is the project "MP-101" about.

signaling    there    immuno    alone    fact    quality    prematurely    7m    sales    50x    troublesome    oncology    nervous    painful    drugs    treatment    difficult    people    mp    moderately    gain    excitation    6m    cancer    pain    treat    estimate    prevention    nerves    supply    dependent    combination    acts    sensitization    nerve    big    20181    patients    stop    brain    diagnosed    diminishing    prolonged    leads    trials    excessive    18m    neuropathy    worldwide    constant    causing    damage    lasting    pharmaceuticals    none    peripheral    market    impeding    innovation    risks    glutamate    performing    modulator    chemotherapy    endings    sensory    plan    suffering    101    eurotransmitter    strength    lowering    world    strategy    agents    stimulation    unpleasant    central    therapies    normal    substantial    preventing    clinical    cipn    life    neuropathic    chain    regardless    patient    spine    submitting    painkiller    group    metys    chemotherapeutic    40    approval    drafted    regulatory    2m    symptoms    sedating    scaling   

Project "MP-101" data sheet

The following table provides information about the project.

Coordinator
METYS PHARMACEUTICALS AG 

Organization address
address: GERBERGASSE 30
city: BASEL
postcode: 4001
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://metys-pharma.ch/en/about
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METYS PHARMACEUTICALS AG CH (BASEL) coordinator 50˙000.00

Map

 Project objective

There will be over 18m new cases of cancer worldwide in 20181, out of which about 3,7m in Europe alone. Studies estimate that up to 40% of all cancer patients develop chemotherapy-induced peripheral sensory neuropathy (CIPN), meaning over 1,6m patients in EU and 7,2m world-wide may experience CIPN each year. This group is only growing in number, due to the constant growth in new cases of diagnosed cancer. The new immuno-oncology drugs are increasingly being used in combination with chemotherapy. CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms in the central nervous system, lowering the patient’s life quality and impeding patient’s normal activities. In fact, the CIPN induced pain is so strong and troublesome that many patients stop their cancer chemotherapy treatment prematurely. Regardless of the big and increasing number of people suffering from CIPN, only moderately effective therapies are available for the treatment, none specifically developed for CIPN, with substantial risks and unpleasant side effects for patients. Metys Pharmaceuticals is developing MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain. Chemotherapeutic agents damage peripheral nerve endings, causing excessive signaling and sensitization which involves the eurotransmitter glutamate: this leads to prolonged excitation of the central nerves of the spine and brain. MP-101 acts as glutamate modulator, diminishing the strength of glutamate stimulation, or, if given early enough, preventing glutamate-dependent sensitization. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. The innovation project will focus on scaling up the production by 50x, performing phase 2 clinical trials, before submitting results to gain regulatory approval for sales across Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-101" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-101" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ARON (2020)

Assay-Ready Organ Network

Read More  

TANDEM (2019)

Tuneable Acoustic Noise DampEning Material

Read More  

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More